For Humanity.
Saving Lives Through the Power of Early Cancer Detection

Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to bein control of their own health.

Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leavingGroupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is“Play Hard, Work Harder”.

Professor Allen Chan is the Chair Professor of Chemical Pathology and the Chief of Service for the clinical service of the Department of Chemical Pathology of The Chinese University of Hong Kong (CUHK). He received his undergraduate medical training from the University of Hong Kong and started his PhD training in the Department of Chemical Pathology at CUHK in 2001 under the supervision of Professor Dennis Lo.

His main research interest is developing new diagnostic approaches based on circulating DNA analysis. The applications of his inventions cover noninvasive prenatal testing, cancer diagnostics, organ transplant and autoimmune diseases monitoring. To date, he has published 169 peer-reviewed articles with a total citation of over 11,000 and an h-index of 56. He is a co-inventor of over 1,500 patent applications with over 900 granted globally covering 73 inventions on molecular diagnostics. Among his inventions, the noninvasive prenatal test for Down syndrome is the most notable. This test has been adopted in over 70 countries with millions of tests performed each year.

Professor Chan is also an entrepreneur and he co-founded a number of biotechnology companies with Professors Dennis Lo and Rossa Chiu. One of his companies, Cirina, was acquired by GRAIL for over USD 300 million in 2017, and GRAIL was acquired by Illumina, at a cost of over USD 7.1 billion in 2021.

Ben Cheng is the member of Prenetics’ Board of Directors. He is also the president and CEO of C Capital, where he leads its sought-after deals and actively engages in major venture capital and private equity investments across the sectors of healthcare, consumer and technology. Named as “China’s Top 20 Most Outstanding Investor” by Lieyun.com in 2020, Mr. Cheng has helped execute many investments in the aforementioned “unicorns”, such as Xpeng Motors, NIO, JD Logistics, Gojek, FTA, Xiaohongshu and Pony.ai. Mr. Cheng is alsoa member of the Advisory Committee of Vertex SEA Fund, a subsidiary of Temasek Holdings, and a member of Venture Committee of Hong Kong Venture Capital and Private Equity Association.

Mr. Cheng has also served as a General Manager at New World Development since March 2016 and the Chief Investment Officer of Private Equity Department at ARTA TechFin Corporation Ltd since July 2021. Prior to his current roles, Mr. Cheng was an investment banker at Bank of America Merrill Lynch and Standard Chartered Bank. Mr. Cheng holds a bachelor’s degree in Quantitative Finance with honors from The Chinese University of Hong Kong.

Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca plc, and an independent director of HUTCHMED (China) Limited. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer.

Prof. Mok was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and have played a significant role in defining current practice. Prof. Mok has also engaged in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO.